Pfizer CentreOne launches Enviero green-chemistry progesterone API16 Apr 2018
Carbon footprint reduced by more than 70%.
Pfizer CentreOne has introduces Enviero progesterone into the API marketplace. Enviero progesterone is produced by a first-of-its-kind progesterone synthesis developed by Pfizer that reduces waste, greenhouse gas emissions and use of hazardous solvents. Results include cutting the carbon footprint of the progesterone manufacturing process by more than 70% and eliminating the use of metal catalysts. Pfizer CentreOne is a global contract manufacturing organization embedded within Pfizer Inc. and a leading supplier of steroid and hormone APIs and intermediates.
"Enviero green-chemistry progesterone represents a step change in progesterone API synthesis,” said Greg Scanlon, API business lead for Pfizer CentreOne. “And it’s in keeping with Pfizer’s commitment to reduce its impact on the environment.” Developed over 12 years, Enviero progesterone is manufactured via a proprietary biocatalytic process based on plant sterols. Scanlon continued: “We are pleased to offer Enviero progesterone to customers looking for a reliable supply of high-quality progesterone for their medicines."
While new to Pfizer CentreOne customers, Enviero progesterone has been used by Pfizer as an intermediate in the manufacture of its own medications for the past 4 years. More than 500 metric tons have been manufactured to date for internal use.
The compound is manufactured exclusively in the US at Pfizer’s Kalamazoo, Michigan, facility. As with all Pfizer CentreOne APIs, all processing steps for Enviero progesterone are performed under Pfizer’s stringent quality management system, and the compound is backed by technical and regulatory support for the life of the product.
Enviero progesterone is the first API to be launched from Pfizer CentreOne’s green-chemistry program. According to the US Environmental Protection Agency, “Green chemistry is the design of chemical products and processes that reduce or eliminate the use or generation of hazardous substances.” Green chemistry is applied at the process level – in this case, API synthesis – to minimize waste and pollution upfront.
BIA Separations expands with new upstream processing facility
20 Sep 2018
Provides single source of expertise for scaled production of complex biologics for gene therapy and vaccines.Read more
Sanofi to refocus two global business units
19 Sep 2018
The new Primary Care and China & Emerging Markets global business units are expected to launch at the beginning of 2019.Read more
Experts warn trade and patent changes could increase healthcare cost by $100bn over next 5 years
18 Sep 2018
China is harmonizing to ICH standards at feverish pace and will force poor quality manufacturers out of market.Read more
Recipharm connects to European Hub for serialisation compliance
18 Sep 2018
Connection allows the marketing authorisation holders within the Recipharm Group to continue to supply medicines to patients post the EU FMD implementation date.Read more
Bosch to unveil new laboratory device for continuous manufacturing
18 Sep 2018
The Xelum R&D offers pharmaceutical manufacturers an ideal start to continuous OSD production.Read more
Partnership to deliver integrated, off-the-shelf biosimilar manufacturing solutions
17 Sep 2018
Pall and Aetos to advance the market impact of biosimilars and deliver lower-priced, high-quality options to end users.Read more
Cambrex expands manufacturing footprint with acquisition
16 Sep 2018
Completed acquisition adds formulation development and finished dosage manufacturing capabilities to Cambrex’s existing global API manufacturing network.Read more
NMPA approves fruquintinib capsules for metastatic colorectal cancer
13 Sep 2018
Fruquintinib - innovative medicine that has not previously been launched in China or internationally - provides a new therapeutic approach for metastatic colorectal cancer patients.Read more
Aptar Pharma to showcase an industry first
12 Sep 2018
PureHale is a new portable drug delivery device designed for upper respiratory care.Read more
Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio
11 Sep 2018
The Sandoz US portfolios to be sold to Aurobindo include approximately 300 products, as well as additional development projects.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation